(3S,7S)-3-amino-7-(methylamino)-4,6-dioxooctanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S,7S)-3-amino-7-(methylamino)-4,6-dioxooctanamide
• 化学式: C₉H₁₇N₃O₃
• 分子量: 215.25
• InChiKey: RPTZEGCOGSANEJ-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] ANTIBODIES THAT BIND TO HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1)<br/>[FR] ANTICORPS QUI SE LIENT AU LIGAND 1 DE LA MORT PROGRAMMÉE HUMAINE (PD-L1)
  申请人：MERCK SHARP & DOHME

  公开号：WO2014100079A1

  公开（公告）日：2014-06-26

  The present disclosure provides isolated antibodies that specifically bind to human PD-L1, as well as antigen binding fragments of such antibodies, and kits comprising the anti-PD-L1 antibodies or binding fragments and a set of reagents for detecting a complex of the antibody, or antigen binding fragment thereof, bound to human PD-L1. The antibodies and antigen binding fragments of this disclosure are useful for immunohistochemical detection of human PD-L1 expression in tissue samples. Nucleic acid molecules encoding the antibodies and antigen binding fragments of this disclosure, as well as expression vectors and host cells for expression thereof, are also provided.
• [EN] CMV NEUTRALIZING ANTIGEN BINDING PROTEINS<br/>[FR] PROTÉINES SE LIANT À L'ANTIGÈNE NEUTRALISANT LE CMV
  申请人：MERCK SHARP & DOHME

  公开号：WO2014200898A2

  公开（公告）日：2014-12-18

  The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.
• [EN] ANTI-TIGIT ANTIBODIES<br/>[FR] ANTICORPS ANTI-TIGIT
  申请人：MERCK SHARP & DOHME

  公开号：WO2016028656A1

  公开（公告）日：2016-02-25

  The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
• [EN] ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS<br/>[FR] ANTICORPS ET FRAGMENTS DE FIXATION À L'ANTIGÈNE ANTI-LAG3
  申请人：MERCK SHARP & DOHME

  公开号：WO2016028672A1

  公开（公告）日：2016-02-25

  The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
• [EN] ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS<br/>[FR] ANTICORPS NEUTRALISANT LE VIRUS SYNCYTIAL RESPIRATOIRE HUMAIN
  申请人：MERCK SHARP & DOHME

  公开号：WO2017075124A1

  公开（公告）日：2017-05-04

  The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.